We describe a new rat immunoglobulin M monoclonal antibody (CH-F42) that recognizes a subset (1.5% to 8%) of normal peripheral blood T lymphocytes. The phenotype of these cells was determined, using dual-color immunofluorescence, to be CD2+, CD3'. CD4'. CD5'. CD7-, CD8-. They do not express T-cell activation markers, and are positive for UCHLl (CD46RO). but negative for 2H4 (CD45RA). The antigen was expressed on circulating malignant cells in Shzary syndrome (four of four cases) and adult T-cell lymphoma-leukemia (ATLL) (four of six cases) and negative in a variety of other hematologic malignancies tested. These included chronic and acute lymphoid leuke-
ling evidence in support of the hypothesis linking these malignant proliferations to a common normal precursor cell.
MATERIALS AND METHODS
CH-F42 is a rat MoAb of immunoglobulin M (IgM) isotype arising from a fusion between YB2/3.0 Ag.20 rat myeloma cells and spleen cells from an A 0 strain rat immunized with peripheral blood mononuclear cells (PBMNC) from a patient with hairy cell leukaemia (HCL). After polyethylene glycol fusion, the cells were distributed into 24-well plates and supernatants tested against liquid nitrogen stored HCL cells for indirect immunofluorescent staining. Wells showing positivity were cloned on soft agar'3 and the supernatants screened by the peroxidase antiperoxidase (PAP) technique on cytocentrifuge preparations of HCL and normal PBMNCs. During the course of screening clones derived from a positive well, the clone CH-F42 was detected that failed to react with HCL cells but reacted strongly and consistently with a minor subpopulation of normal PBMNC. The cloned hybridoma was grown as an ascites in rats and the IgM fraction partially purified from the ascitic fluid by Sephacryl S-300 (Pharmacia, Central Milton Keynes, Bucks, UK) chromatography. CH-E25 was produced and grown as above, and is of the same isotype. It has failed to react with any human hemic cells tested to date by immunofluorescence or immunoperoxidase staining, and is used as a negative control in all tests involving CH-F42. OKT4 and OKTlO were purchased from Ortho Diagnostics Ltd (Raritan, NJ). Other OKTseries antibodies as well as NA1/34 and 3A1 were tissue culture supernatants of hybridomas obtained from the American Type Culture Collection (ATCC) and cultured in our laboratory. T1 (CD5) was obtained from DAKO Ltd (High Wycombe, Bucks, UK), 4B4 (CD29), 2H4 (CD45RA); TQ1 from Coulter Immunology (Luton, Beds, UK); SL8 (CD71) from Seralab Ltd (Crawley Down, Sussex, UK); and UCHLl (CD45RO) from Cymbus Bioscience (Southhampton, Hampshire, UK). Campath 1 (CD52), Campath 6 (CD25), YTH24.5 (CD45), YTH 80.103 (CD45R), and YAML 555.6 (HLA-DR) were kindly donated by Dr H. Waldmann (Department of Pathology, University of Cambridge).
Biotinylation of antibodies. The partially purified IgM fractions of CH-F42 and CH-E25 obtained by Sephacryl S-300 chromatography were treated in 0.1 mol/L carbonate buffer (pH 9.0) containing 0.5 mol/L NaCl with biotinamidocaproate-N-hydroxysuccinimide ester (BACNHS) dissolved at 2 mg/mL in dimethyl sulphoxide (100 pg BACNHS per 1 mg IgM protein). Coupling was performed at O°C with stirring for 2 hours. The reaction mixture was chromatographed on sephadex G25 in phosphate-buffered saline (PBS) to remove free biotin products, and the protein peak was made 1% with bovine serum albumin (BSA) and preserved with sodium azide.
Mononuclear cells (MNC) were isolated from heparinized peripheral blood of patients or normal donors by Ficoll-Hypaque density gradient centrifugation. Whole blood from normal donors was preincubated for 1 hour at 37OC with 1 mg/mL carbonyl iron to eliminate phagocytic cells. Plastic-adherent cells were removed from Ficoll-separated MNC suspensions by incubation in plastic tissue culture flasks (Corning) at 37OC for 1 hour, in HEPES-buffered Hanks' balanced salt solution (H/HBSS). Nonadherent cells were decanted and washed.
Continuous cell lines were grown in RPMI-1640 or Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), at 37OC in an atmosphere of 5% CO, in air.
Cytocentrifuge preparations were air-dried overnight and fixed for 1 minute in acetone before staining by the PAP m e t h~d . '~ Indirect immunofluorescent staining of cultured cells and PBMNC from patients or voluntary blood donors was performed by standard methods.I4 Samples for dual immunolabeling were further treated with biotin-coupled CH-F42 for 30 minutes on ice, washed, and incubated for 30 minutes with avidin-D-aminomethylcoumarin acetic acid (AMCA) for flow cytometry or avidin-D-rhodamine isothiocyanate (RITC) (both Vector Laboratories) for microscopic analysis. Samples were resuspended in 0.85% saline containing 1% paraformaldehyde for analysis by fluorescence microscopy or flow cytometry.
Samples were examined by epi-illumination on a Zeiss Ultraviolet microscope fitted with the appropriate FITC and RITC excitation and barrier filters.
Flow cytometry was performed on the Cambridge Medical Research Council custom-built dual laser flow ~yt0meter.I~ The data were collected in list mode and processed by custom analysis and display programs.I6
Isolation of CH-F42' normal cells. CH-F42+ cells were isolated by means of an immunomagnetic cell separation technique using superparamagnetic microspheres; M-450 Dynabeads (Dynal, Oslo, Norway) coated with monoclonal IgM (CH-F42) antibodies partially purified from ascitic fluid, and physically adsorbed to the surface of the Dynabeads following the manufacturer's protocol. The relative number of cells that bound CH-F42 beads was determined by a rapid, one step phenotyping technique." CH-F42 beads were then added to 5 x lo' MNC/mL in culture medium (RPMI-1640) containing DNAse (2.5 pg/mL), at a ratio of 5 beads per rosetteforming cell in an ice bath. After centrifugation at 400g for 2 minutes at 4OC and gentle resuspension of the pellet, the rosetted cells were positively selected using a magnetic particle concentrator 
Indirect immunofluorescence of cells in suspension.
(Dynal, MPC-1). The process was repeated if necessary. Isolated cells were washed several times in culture medium with DNAse, which was excluded from the final washing step. All subsequent stages in the processing of cells for electron microscopy were monitored by light microscopy to ensure that the processing did not disrupt rosettes or lead to the formation of artifactual aggregates that might be mistakenly interpreted as rosettes. The rosetted cells were observed in wet preparations by phase contrast microscopy.
Electron microscopy. One milliliter of each suspension of cells and antibody coated Dynabeads was fixed by rapid dilution in to 5 mL 1% glutaraldehyde, 0.1 mol/L sodium cacodylate, pH 7.2 at room temperature. After 10 minutes the fixation was quenched by the addition of 5 mL 1 mol/L ethanolamine, pH 7.2. After 30 minutes the cells were resuspended in 1% osmium tetroxide, 0.1 mol/L sodium cacodylate, pH 7.2 for 15 minutes at room temperature and then washed twice in sodium cacodylate. This procedure prevented the formation of nonspecific aggregates while still preserving good ultrastructural morphology." Fixation also prevented the spontaneous disassembly of rosettes that may occur if the samples are stored for some time in a refrigerator. Ultrathin sections were observed in a Zeiss electron microscope.
Preliminary antigen characterization. Trypsin, pronase, neuraminidase, sodium metaperiodate, puromycin, and tunicamycin were obtained from Sigma Chemical Co (Poole, Dorset, UK). Cell suspensions were washed in PBS, resuspended in a solution of the appropriate concentration of enzyme in PBS, and incubated at 37OC for 1 hour in 24-well tissue-culture plates (Nunclon, Denmark) along with control samples containing no enzyme. In each case, the cells were resuspended every 20 minutes to facilitate uniformity of exposure to the enzyme. Alternatively, cells were treated with 2 mmol/L sodium metaperiodate in PBS for 10 minutes on ice. The cells were then washed twice in PBS to remove enzyme or reagent, and finally washed in PBS containing 0.1% sodium azide and analyzed by immunofluorescence.
Inhibition of N-glycosylation. Cultured K562 or Jurkat cells were treated with 1 Mg/mL puromycin (Sigma) for 2 hours in serum-free culture medium. The cells were then washed twice in PBS and incubated with 50 mU/mL neuraminidase or 4 mg/mL pronase in PBS for 30 minutes to remove all detectable CH-F42 antigen, washed again, immediately resuspended in culture medium containing up to 10 pg/mL tunicamycin, and incubated for 4 hours. After washing again, the cells were placed in medium supplemented with 10% FCS (Biological Industries) containing tunicamycin. Samples were taken from replicate cultures at various intervals for testing by immunofluorescence.
RESULTS
The normal CH-F42+ cell. Peripheral blood leukocytes from normal donors were tested for reactivity with CH-F42 by suspension immunofluorescence and PAP on cytosmears. One percent to six percent of total P B M N C expressed the antigen in each case, usually with intense staining (Fig 1) . Depletion studies indicated CH-F42+ cells were confined to the lymphocyte population ( They were also found to express 4B4 (CD29). TQI. and low amounts of UCHLI(CD45RO). and were negative for 2H4 (CD45RA) and YTH80.103 (CD45R). The phenotypic profile was invariable within and among samples taken from several individuals. There was no evidence of CH-F42 expression in mononuclear cells derived from lymphoid tissue including bone marrow, thymus, tonsil, lymph node, or spleen ( Table I) . Comparison of the results obtained by the PAP technique and suspension immunofluorescence for these and other sources of cells showed that there was no evidence of cytoplasmic expression of CH-F42 in the absence of surface expression.
Normal circulating cells positively selected using CH-F42+ated immunomagnetic particles were examined by electron microscopy. The ultrastructural morphology of these cells (Fig 2) was unremarkable, and showed a typical small, nongranular lymphocyte. There was no evidence of the cerebriform nuclear morphology characteristic of Stzary cells.
Distribution of CH-F42 antigen in hematologic malignancies. Samples of fresh or cryopreserved leukocytes from patients with various leukemias and lymphomas were tested by suspension immunofluorescence for reactivity with CH-F42 ( For cells expressed CH-F42. Figure 3 shows the PBMNC cytosmear of a Stiary patient with 56% of cells expressing
In view of the variability of CH-F42 expression in CTCL cases, we performed dual-color immunofluorescence staining on further samples to assess the extent of possible contamination by normal cells. Flow cytometric analysis showed these cell populations to be homogeneous with respect to lineage-and maturation-associated markers. In each case a subset of the population expressed CH-F42. The phenotypes of these malignant populations are given in Table 4 . Further samples from ATLL patients were not available for dual-labeling. Based on the phenotypes, these cases may be classified into three groups: (1) classical SS with the phenotype of mature T-helper cells (patients A and B); (2) SS with atypical phenotype (patients C and D); and (3) ATLL. Patient C expressed the phenotype of a common thymocyte, usually associated with T-ALL. Patient D displayed all the clinical characteristics of SS despite the unusual phenotype of this population, which apart from the low-density expression of YTH80.103 (CD45R) and 2H4 (CD45RA) was consistent with CD5+, slg-B-CLL. T-cell receptor @-gene rearrangement studies on this clone showed its T-cell nature. In none of the samples examined did the malignant cells express CD7.
Studies of surface markers associated with functional subsets of T lymphocytes showed potentially important similarities and differences between the two disease groups.
CH-F42.
Phenotypes of malignant CH-F42' cells. (CD29). 2H4 and YTH80.103 were either negative or expressed at low density. The T4+ Skzary cells (patients A, B, and C) expressed UCHLl (CD45RO) at high density, while the CH-F42+ ATLL cells expressed very low levels of this epitope. Of the cell lines tested, CH-F42 was expressed only on K562 (myeloid/ multipotential) and Jurkat (T) cells ( Table 5 ). The percentage of cells expressing detectable amounts of the antigen and the median intensity of surface fluorescence varied considerably with the proliferative state of the cultured cells in these cell lines. The nature of this variability is under investigation.
The CH-F42 antigen displays sensitivity to trypsin and pronase, and additionally is removed in a concentration-dependent manner by exposure of the cells to neuraminidase. An amount of 25 mU/mL of this enzyme at 37OC for 30 minutes removed almost all detectable expression of CH-F42, and higher concentrations destroyed all detectable antigen. Incubation of cells with 2 mmol/L sodium metaperiodate for 10 minutes also resulted in complete destruction of the antigen. Sialic acid residues thus appear to play an important role in the topography of the CH-F42 antigen, and the sensitivity to proteases suggests the molecule is a sialoglycoprotein. The antigen is fully re-expressed within 12 hours after enzyme treatment, and treatment of cultured cells with tunicamycin, which inhibits N-glycosylation, does not appear to affect CH-F42 re-expression. Attempts to isolate the antigen by Expression in continuous cell lines.
Preliminary characterization of the antigen.
conventional methods of immunoprecipitation have been unsuccessful so far.
DISCUSSION
Studies of the distribution of the CH-F42 antigen showed its expression to be restricted to the subset of T lymphocytes with the CD4+, CD7-, CD8-phenotype. Studies of a range of hematologic malignancies showed that CH-F42 is only expressed to varying degrees in two types of relatively uncommon T-cell malignancy: SS and ATLL. The distribution of the antigen among cultured cell lines is curious in that while reacting with fresh SS and ATLL cells, it is not expressed on the CD7-cell line HUT-78 derived from a patient with SS" or with MT2, an HTLV-1-induced cell line.*' The consistent finding that K562 cells are CH-F42+ cannot be explained at present.
The nature and distribution of the CH-F42 antigen appear to represent a previously unreported set of findings. There were major differences in the reactivity of CH-F42 and BE2, an antibody that had originally been thought to be specific for CTCL." Thus, while CH-F42 failed to react with HUT-78 and Epstein Barr virus+ B-cell lines, BE2 bound to these cell lines but failed to react with K562, which expressed the CH-F42 antigen. More recent studies have also demonstrated the BE2 antigen in mantle and marginal zone B lymphocytesz2 where CH-F42 was not shown to be reactive.
CH-F42 does not appear to be an activation antigen in that increased numbers of CH-F42+ cells are not seen in lympho- cytes cultured for up to 6 weeks in the presence of concanavilin A (conA) and IL-2 or in situations where lymphocytes might be expected to be chronically activated, as, for example, rheumatoid synovial fluid (M.T. Rana, unpublished observations, April 1989). It is proposed that the restricted distribution of the CH-F42 antigen provides a vital link in the elucidation of a functional or an ontogenic relationship between the malignant cells in ATLL and SS, and a common normal counterpart.
Several attempts have been made to identify the normal counterpart of the SBzary cell, based on the premise that the characteristic nuclear morphology would also be an attribute of the normal precursor. Indeed, candidates for precursor cells have been identified in normal peripheral blood based on morphology alone: ' and some of these have been demonstrated to express the CD4+ CD7-CD8-phenotype typical of circulating SCzary cells.24 ATLL-like morphology has also been described in normal CD4+, CD8-lymphocytes that express CD7.24 However, electron microscopic examination of the normal CH-F42+ cell revealed a small mature nongranular lymphocyte, showing no evidence of the cerebriform nuclear pattern characteristic of Stzary cells. Expression of CD7 has been found to be the most consistent marker of T-lymphoproliferative disorders other than SS and ATLL.2.4' In normal lymphopoiesis this molecule is present on the earliest detectable T-committed ~ells:~,~~ and spans the entire process of T-cell maturation. CD7 is a product of the Ig gene superfamily." Although its function is yet to be conclusively determined, there is evidence suggesting that this molecule may act as the T-cell Fc receptor for IgM." It undergoes rapid modulation45 and mobilizes cytoFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From plasmic calcium when bound by and is capable of transduction of comitogenic signals in T-cell pr~liferation.~' Thus, the nonexpression of CD7 must be considered an important feature in normal and malignant T cells. Taking into consideration reports that CD7-T cells appear to be restricted within the CD4+ subset, wherein they represent only a minor proportion of cells,"8 the additional finding that normal CD7-T cells and the CD7-malignant cells in both SS and ATLL express the highly restricted sialoglycan epitope recognized by CH-F42 presents strong evidence that these malignancies may be derived from the same functional subset of CD4+ cells. The question of whether some T cells lose CD7 expression or whether there is a distinct CD7-lineage remains unanswered. Notwithstanding the high relative incidence of the "classical" S6zary phenotype, CTCL displays phenotypic heterogeneity. CH-F42+ circulating cells in CTCL displayed phenotypic profiles that suggest the antigen is expressed over a range of T-cell maturation stages. There may be a developmental and/or functional relationship between the skin and CD7-, CH-F42+ T cells. However, the situation with regard to the expression of CD7 by CTCL cells infiltrating the skin is unclear at present. Thus, CTCL skin infiltrates have been reported both to or contain" CD7+ cells. The problem is complicated by the difficulties in distinguishing between malignant and reactive normal cells in these infiltrates. We are presently conducting immunohistochemical studies on normal and CTCL-involved skin using
We propose the "target" cells of the transforming event(s) in SS of classical phenotype and ATLL are identical, and the observed differences in immunoregulatory function of these malignant cells are due mainly to the differences in etiology of the diseases. The CH-F42 antigen may identify a heterogeneous population of CD7-T cells that display skin tropism, and could possibly be involved in the homing mechanism, or the interaction of these lymphocytes with other cell types in the skin. The propensity for skin tropism of malignant cells in CTCL and ATLL may be the manifestation of a normal immune process, in which the transformed cells attempt to behave physiologically. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
